May 20, 2019 / 02:00PM GMT
Carter Lewis Gould - UBS Investment Bank, Research Division - Large Cap Biotech Analyst
Good morning. My name is Carter Gould, senior biotech analyst here at UBS. Next up is Regeneron Pharmaceuticals. Joining me onstage, Marion McCourt, SVP of Commercial; Jay Markowitz, Head of Portfolio Strategy. Both, thank you very much for joining us today. I'm going to keep going back and forth with the -- so like I said, thank you.
Questions and Answers:
Carter Lewis Gould - UBS Investment Bank, Research Division - Large Cap Biotech AnalystI guess first question, we've got a lot to get through because you guys are one of the more diversified companies, lots of dynamic stuff to talk about.
I guess first thing, Jay, a question for you. You've been in the company around 3 years now, sort of you're -- over that 3 years, we've seen oncology really increase as a point of focus for the company. Can you maybe -- starting with Libtayo and then the bispecifics and the evolution of that and when I looked at sort of like your Phase I programs over the past year,
Trustpilot
